Therefore neutralizing anti-TNF-α biotherapeutics such as golimumab (Simponi), infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), or etanercept (Enbrel) are popular steroid-sparing agents in the treatment of TNF-α–mediated inflammation in many rheumatologic disorders, including chronic plaque psoriasis, juvenile idiopathic arthritis, ulcerative colitis, and Crohn's disease for many years.2 This evidence concerns the gene TNF and juvenile idiopathic arthritis.